ELV Elevance Health

XNYS Up Alert

Health Care

· How we analyze

About the company

Elevance Health, formerly Anthem, is a US health insurer. The company runs plans under the Blue Cross Blue Shield brand in many states, for employers, Medicaid and Medicare, and offers health and pharmacy services through Carelon. As of Oct 13, 2026

Fact sheet (from the annual report) Health insurance and health plans · Indianapolis, USA

Elevance Health is a health insurer in the United States with managed care plans for individuals, employer groups and for Medicaid and Medicare. As an independent licensee of Blue Cross and Blue Shield, the company operates in California, Colorado, Georgia and Indiana, among other states. The Health Benefits segment offers full-risk health insurance as well as dental, vision and supplemental insurance. The CarelonRx segment provides pharmacy services such as mail-order and specialty pharmacies, claims processing and formularies for its own and external customers. In March 2024 the acquisition of Paragon Healthcare added outpatient infusion centers to CarelonRx.

Automatically summarized from SEC annual report (10-K, filed Feb 6, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026

What the methods say about Elevance Health

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today −2.3%
  • 7 days −4.3%
  • 30 days +6.4%
  • 1 year +23.1%
Day range (last trading day)
−0.7%Price at 18% of the range+3.1%
52-week range
−34.8%Price at 83% of the range+6.9%
Distance from the all-time high
−25.7%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:ELV

Fundamental analysis

Elevance Health · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 6, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet · 1 without data 3 of 7 criteria met Growth Revenue and earnings per share 6 of 7 criteria met Dividend Level, consistency, coverage 7 of 7 criteria met Financial strength Piotroski, debt, liquidity 6 of 6 criteria met

Quality 3 of 7 met · 1 without data

  • no data: Gross margin above 40% reported cost of revenue covers only part of the costs (margin more than 60 percentage points above the operating margin)
  • not met: Operating margin above 15% 3.6%
  • not met: Net margin above 10% 2.8%
  • not met: Return on equity above 15% 12.9%
  • not met: Free cash flow margin above 10% 1.6%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 36.1%
Operating margin

3.6% Fiscal year 2025

Rank 25 of 100: higher than 25% of 192 peers (All). weak.

Rank 33 of 100: higher than 33% of 20 peers (Sector). medium.

Median Health Care: 18.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

2.8% Fiscal year 2025

Rank 21 of 100: higher than 21% of 237 peers (All). weak.

Rank 29 of 100: higher than 29% of 26 peers (Sector). weak.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

12.9% Fiscal year 2025

Rank 42 of 100: higher than 42% of 218 peers (All). medium.

Rank 45 of 100: higher than 45% of 21 peers (Sector). medium.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

4.7% Fiscal year 2025 (total assets at year end)

Rank 42 of 100: higher than 42% of 238 peers (All). medium.

Rank 37 of 100: higher than 37% of 26 peers (Sector). medium.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

36.1% Fiscal year 2025

Rank 50 of 100: higher than 50% of 239 peers (All). medium.

Rank 44 of 100: higher than 44% of 26 peers (Sector). medium.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

1.6% Fiscal year 2025

Rank 21 of 100: higher than 21% of 213 peers (All). weak.

Rank 22 of 100: higher than 22% of 25 peers (Sector). weak.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

3.2B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 6 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +8.3%
  • met: Over 5 years, revenue grew by more than 5% per year +10.3%
  • met: Over 10 years, revenue grew by more than 5% per year +9.7%
  • not met: Over 3 years, EPS grew by more than 5% per year +0.5%
  • met: Over 5 years, EPS grew by more than 5% per year +7.0%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +12.5%
Revenue growth 3 years

+8.3% per year

Rank 48 of 100: higher than 48% of 230 peers (All). medium.

Rank 62 of 100: higher than 62% of 25 peers (Sector). medium.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+10.3% per year

Rank 47 of 100: higher than 47% of 217 peers (All). medium.

Rank 54 of 100: higher than 54% of 25 peers (Sector). medium.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+9.7% per year

Rank 61 of 100: higher than 61% of 157 peers (All). medium.

Rank 34 of 100: higher than 34% of 19 peers (Sector). medium.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+0.5% per year

Rank 25 of 100: higher than 25% of 157 peers (All). weak.

Rank 34 of 100: higher than 34% of 22 peers (Sector). medium.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+7.0% per year

Rank 27 of 100: higher than 27% of 146 peers (All). weak.

Rank 48 of 100: higher than 48% of 20 peers (Sector). medium.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+10.4% per year

Rank 51 of 100: higher than 51% of 140 peers (All). medium.

Rank 58 of 100: higher than 58% of 20 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 6.84 USD
  • met: Payout ratio at most 60% of earnings 27%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +12.5%
  • met: Free cash flow per share covers the dividend 2.1x
  • met: Dividends paid over the last 5 years covered by free cash flow 23% of free cash flow
Payout ratio

27% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+12.5% per year

Rank 67 of 100: higher than 67% of 118 peers (All). strong.

Rank 59 of 100: higher than 59% of 16 peers (Sector). medium.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Free cash flow coverage

2.1x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 6 of 6 met

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • met: Long-term debt no higher than equity 0.73
  • met: Current assets cover current liabilities 1.54
  • met: Positive equity 43.9B USD
  • met: In 5 years, share count up by at most 5% −11.7%
  • met: Free cash flow positive in the last fiscal year 3.2B USD
Piotroski F-Score

7 of 9 Fiscal year 2025

Rank 72 of 100: higher than 72% of 134 peers (All). strong.

Rank 63 of 100: higher than 63% of 19 peers (Sector). medium.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.73 at fiscal year end

Rank 42 of 100: lower than 42% of 199 peers (All). medium.

Rank 42 of 100: lower than 42% of 18 peers (Sector). medium.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.54 at fiscal year end

Rank 54 of 100: higher than 54% of 215 peers (All). medium.

Rank 40 of 100: higher than 40% of 26 peers (Sector). medium.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−11.7% in 5 years

Rank 85 of 100: lower than 85% of 199 peers (All). strong.

Rank 85 of 100: lower than 85% of 24 peers (Sector). strong.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • not met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+10.3% per year), at least as fast as the sector median.
  • Light yellow: Net income (total) grew over 5 years (+4.4% per year), more slowly than the sector median; per share +7.0% per year.
  • Light yellow: Net margin 2.8%, below the sector median (12.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 84.9B USD · Net income 2.5B USD · Net margin 2.9%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 90.0B USD · Net income 3.8B USD · Net margin 4.3%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 92.1B USD · Net income 3.8B USD · Net margin 4.1%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 104.2B USD · Net income 4.8B USD · Net margin 4.6%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 121.9B USD · Net income 4.6B USD · Net margin 3.8%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 138.6B USD · Net income 6.1B USD · Net margin 4.4%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 156.6B USD · Net income 6.0B USD · Net margin 3.8%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 171.3B USD · Net income 6.0B USD · Net margin 3.5%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 177.0B USD · Net income 6.0B USD · Net margin 3.4%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 199.1B USD · Net income 5.7B USD · Net margin 2.8%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 199.1B USD · Net income 5.7B USD · Net margin 2.8%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 3.6 USD operating income and 2.8 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue199.1B USD100.0%
Operating income7.2B USD3.6%
Cost of revenue and operating expenses191.9B USD96.4%
Net income5.7B USD2.8%
Interest expense1.4B USD0.7%
Taxes & other (net)135.0M USD0.1%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 5.2% to 3.6%.

Operating marginNet margin
  1. Fiscal year 2016: Operating margin 5.7% · Net margin 2.9%
  2. Fiscal year 2017: Operating margin 4.6% · Net margin 4.3%
  3. Fiscal year 2018: Operating margin 5.9% · Net margin 4.1%
  4. Fiscal year 2019: Operating margin 5.8% · Net margin 4.6%
  5. Fiscal year 2020: Operating margin 5.2% · Net margin 3.8%
  6. Fiscal year 2021: Operating margin 5.4% · Net margin 4.4%
  7. Fiscal year 2022: Operating margin 5.4% · Net margin 3.8%
  8. Fiscal year 2023: Operating margin 5.0% · Net margin 3.5%
  9. Fiscal year 2024: Operating margin 4.4% · Net margin 3.4%
  10. Fiscal year 2025: Operating margin 3.6% · Net margin 2.8%

Returns

Return on equity stayed roughly the same in 5 years (12.9%).

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 9.8% · Return on assets 3.8%
  2. Fiscal year 2017: Return on equity 14.5% · Return on assets 5.4%
  3. Fiscal year 2018: Return on equity 13.1% · Return on assets 5.2%
  4. Fiscal year 2019: Return on equity 15.2% · Return on assets 6.2%
  5. Fiscal year 2020: Return on equity 13.8% · Return on assets 5.3%
  6. Fiscal year 2021: Return on equity 16.9% · Return on assets 6.3%
  7. Fiscal year 2022: Return on equity 16.6% · Return on assets 5.9%
  8. Fiscal year 2023: Return on equity 15.2% · Return on assets 5.5%
  9. Fiscal year 2024: Return on equity 14.5% · Return on assets 5.1%
  10. Fiscal year 2025: Return on equity 12.9% · Return on assets 4.7%

Equity and long-term debt

The equity ratio fell in 5 years from 38.3% to 36.1%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 25.1B USD · Long-term debt 15.3B USD
  2. Fiscal year 2017: Equity 26.5B USD · Long-term debt 18.7B USD
  3. Fiscal year 2018: Equity 28.5B USD · Long-term debt 18.1B USD
  4. Fiscal year 2019: Equity 31.7B USD · Long-term debt 19.4B USD
  5. Fiscal year 2020: Equity 33.2B USD · Long-term debt 20.0B USD
  6. Fiscal year 2021: Equity 36.1B USD · Long-term debt 22.8B USD
  7. Fiscal year 2022: Equity 36.3B USD · Long-term debt 23.8B USD
  8. Fiscal year 2023: Equity 39.3B USD · Long-term debt 24.9B USD
  9. Fiscal year 2024: Equity 41.3B USD · Long-term debt 30.9B USD
  10. Fiscal year 2025: Equity 43.9B USD · Long-term debt 31.9B USD

Liquidity (current ratio)

The current ratio stayed roughly the same in 5 years (1.54).

Current ratio
  1. Fiscal year 2016: Current ratio 1.61
  2. Fiscal year 2017: Current ratio 1.55
  3. Fiscal year 2018: Current ratio 1.56
  4. Fiscal year 2019: Current ratio 1.65
  5. Fiscal year 2020: Current ratio 1.55
  6. Fiscal year 2021: Current ratio 1.47
  7. Fiscal year 2022: Current ratio 1.40
  8. Fiscal year 2023: Current ratio 1.44
  9. Fiscal year 2024: Current ratio 1.45
  10. Fiscal year 2025: Current ratio 1.54

Cash flow

Free cash flow fell in 5 years from 9.7B USD to 3.2B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 3.2B USD · Capital expenditure 583.6M USD · Free cash flow 2.6B USD
  2. Fiscal year 2017: Operating cash flow 4.2B USD · Capital expenditure 799.5M USD · Free cash flow 3.4B USD
  3. Fiscal year 2018: Operating cash flow 3.8B USD · Capital expenditure 1.2B USD · Free cash flow 2.6B USD
  4. Fiscal year 2019: Operating cash flow 6.1B USD · Capital expenditure 1.1B USD · Free cash flow 5.0B USD
  5. Fiscal year 2020: Operating cash flow 10.7B USD · Capital expenditure 1.0B USD · Free cash flow 9.7B USD
  6. Fiscal year 2021: Operating cash flow 8.4B USD · Capital expenditure 1.1B USD · Free cash flow 7.3B USD
  7. Fiscal year 2022: Operating cash flow 8.4B USD · Capital expenditure 1.2B USD · Free cash flow 7.2B USD
  8. Fiscal year 2023: Operating cash flow 8.1B USD · Capital expenditure 1.3B USD · Free cash flow 6.8B USD
  9. Fiscal year 2024: Operating cash flow 5.8B USD · Capital expenditure 1.3B USD · Free cash flow 4.6B USD
  10. Fiscal year 2025: Operating cash flow 4.3B USD · Capital expenditure 1.1B USD · Free cash flow 3.2B USD

Share count

The share count fell in 5 years by 11.7% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 268.1M
  2. Fiscal year 2017: Diluted share count 267.8M
  3. Fiscal year 2018: Diluted share count 264.2M
  4. Fiscal year 2019: Diluted share count 260.3M
  5. Fiscal year 2020: Diluted share count 254.3M
  6. Fiscal year 2021: Diluted share count 246.8M
  7. Fiscal year 2022: Diluted share count 242.8M
  8. Fiscal year 2023: Diluted share count 237.4M
  9. Fiscal year 2024: Diluted share count 232.9M
  10. Fiscal year 2025: Diluted share count 224.6M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
6.84 USD · Fiscal year 2025
Dividend growth per year
3 y +10.1%5 y +12.5%10 y +10.6%
Years without a cut
at least 10 as far as the data goes
Payout ratio
of earnings 27% of free cash flow 48%
To shareholders (5 years)
19.2B USD 65% through repurchases
Share count over 5 years
−11.7% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 3.80 USD to 6.84 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 2.60 USD
  2. Fiscal year 2017: Dividend per share 2.70 USD
  3. Fiscal year 2018: Dividend per share 3.00 USD
  4. Fiscal year 2019: Dividend per share 3.20 USD
  5. Fiscal year 2020: Dividend per share 3.80 USD
  6. Fiscal year 2021: Dividend per share 4.52 USD
  7. Fiscal year 2022: Dividend per share 5.12 USD
  8. Fiscal year 2023: Dividend per share 5.92 USD
  9. Fiscal year 2024: Dividend per share 6.52 USD
  10. Fiscal year 2025: Dividend per share 6.84 USD

Payout ratios

The payout ratio rose in 5 years from 21.1% to 27.1%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 28.2% · Payout ratio (free cash flow) 26.1%
  2. Fiscal year 2017: Payout ratio (earnings) 18.8% · Payout ratio (free cash flow) 20.8%
  3. Fiscal year 2018: Payout ratio (earnings) 21.1% · Payout ratio (free cash flow) 29.6%
  4. Fiscal year 2019: Payout ratio (earnings) 17.3% · Payout ratio (free cash flow) 16.4%
  5. Fiscal year 2020: Payout ratio (earnings) 21.1% · Payout ratio (free cash flow) 9.9%
  6. Fiscal year 2021: Payout ratio (earnings) 18.3% · Payout ratio (free cash flow) 15.2%
  7. Fiscal year 2022: Payout ratio (earnings) 20.6% · Payout ratio (free cash flow) 17.0%
  8. Fiscal year 2023: Payout ratio (earnings) 23.5% · Payout ratio (free cash flow) 20.6%
  9. Fiscal year 2024: Payout ratio (earnings) 25.4% · Payout ratio (free cash flow) 33.1%
  10. Fiscal year 2025: Payout ratio (earnings) 27.1% · Payout ratio (free cash flow) 48.2%

What goes back to shareholders

Over 5 years, 19.2B USD went back to shareholders, 65% of it through share repurchases. That is 66% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 684.0M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 2.6B USD
  2. Fiscal year 2017: Dividends paid 704.9M USD · Share repurchases 2.0B USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 3.4B USD
  3. Fiscal year 2018: Dividends paid 776.0M USD · Share repurchases 1.7B USD · New shares issued (including employee plans) 1.3B USD · Free cash flow 2.6B USD
  4. Fiscal year 2019: Dividends paid 818.0M USD · Share repurchases 1.7B USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 5.0B USD
  5. Fiscal year 2020: Dividends paid 954.0M USD · Share repurchases 2.7B USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 9.7B USD
  6. Fiscal year 2021: Dividends paid 1.1B USD · Share repurchases 1.9B USD · New shares issued (including employee plans) not available · Free cash flow 7.3B USD
  7. Fiscal year 2022: Dividends paid 1.2B USD · Share repurchases 2.3B USD · New shares issued (including employee plans) not available · Free cash flow 7.2B USD
  8. Fiscal year 2023: Dividends paid 1.4B USD · Share repurchases 2.7B USD · New shares issued (including employee plans) not available · Free cash flow 6.8B USD
  9. Fiscal year 2024: Dividends paid 1.5B USD · Share repurchases 2.9B USD · New shares issued (including employee plans) not available · Free cash flow 4.6B USD
  10. Fiscal year 2025: Dividends paid 1.5B USD · Share repurchases 2.6B USD · New shares issued (including employee plans) not available · Free cash flow 3.2B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Elevance Health next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison ELV, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
UNH UnitedHealth Group 447.6B USD +11.7%–4.2%2.7%12.0%32.3%3.6%7/9
MCK McKesson Corporation 403.4B USD +11.1%3.6%1.5%1.2%–−2.6%1.4%6/9
CVS CVS Health 402.1B USD +8.4%45.0%1.2%0.4%2.4%29.7%1.9%7/9
CI Cigna 274.9B USD +11.4%21.8%3.3%2.2%14.3%26.4%–7/9
ELV Elevance Health this stock 199.1B USD +10.3%–3.6%2.8%12.9%36.1%1.6%7/9
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+10.3% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 10.3% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light yellow: below sector

+4.4% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +7.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 4.4% per year on average, but more slowly than the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

2.8% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 2.84 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 3.8%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.69 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 0.69 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
199.1B USD
Revenue vs. prior year
+12.5%
Net income (FY)
5.7B USD
Net income vs. prior year
−5.3%
EPS (FY)
25.21 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
−2
Shares held vs. prior quarter
−100.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 6, 2026 · Balance sheet Sep 30, 2026 (filed Oct 21, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 199.1B5.7B 2.8% 25.21 – –
2024Dec 31, 2024 177.0B6.0B 3.4% 25.68 – –
2023Dec 31, 2023 171.3B6.0B 3.5% 25.22 5.92 23%
2022Dec 31, 2022 156.6B6.0B 3.8% 24.81 5.12 21%
2021Dec 31, 2021 138.6B6.1B 4.4% 24.73 4.52 18%
2020Dec 31, 2020 121.9B4.6B 3.8% 17.98 3.80 21%
2019Dec 31, 2019 104.2B4.8B 4.6% 18.47 3.20 17%
2018Dec 31, 2018 92.1B3.8B 4.1% 14.19 3.00 21%
2017Dec 31, 2017 90.0B3.8B 4.3% 14.35 2.70 19%
2016Dec 31, 2016 84.9B2.5B 2.9% 9.21 2.60 28%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 51.4B1.4B 2.7% 6.27 1.72 27%
Q2/26Jun 30, 2026 50.5B1.5B 2.9% 6.71 1.72 26%
Q1/26Mar 31, 2026 50.2B1.8B 3.5% 8.00 1.72 22%
Q4/25*Dec 31, 2025 49.7B547.0M 1.1% – 1.71 –
Q3/25Sep 30, 2025 50.7B1.2B 2.3% 5.32 1.71 32%
Q2/25Jun 30, 2025 49.8B1.7B 3.5% 7.72 1.71 22%
Q1/25Mar 31, 2025 48.9B2.2B 4.5% 9.61 1.71 18%
Q4/24*Dec 31, 2024 45.4B418.0M 0.9% – 1.63 –
Q3/24Sep 30, 2024 45.1B1.0B 2.3% 4.36 1.63 37%
Q2/24Jun 30, 2024 43.9B2.3B 5.2% 9.85 1.63 17%
Q1/24Mar 31, 2024 42.6B2.2B 5.3% 9.59 1.63 17%
Q4/23*Dec 31, 2023 42.6B856.0M 2.0% – 1.48 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $4.7M1 person −$4.7M
6 months $1.4M2 people $5.5M3 people −$4.1M
12 months $2.2M3 people $6.4M5 people −$4.2M

Latest transactions

  • Oct 22, 2026 Kaye Mark Chief financial officer (CFO) Open-market sale 273 shares · $122.1K · SEC
  • Oct 22, 2026 Kaye Mark Chief financial officer (CFO) Open-market sale 827 shares · $368.9K · SEC
  • Oct 22, 2026 Kaye Mark Chief financial officer (CFO) Open-market sale 160 shares · $71.2K · SEC
  • Oct 22, 2026 Kaye Mark Chief financial officer (CFO) Open-market sale 440 shares · $195.3K · SEC
  • Oct 22, 2026 Kaye Mark Chief financial officer (CFO) Open-market sale 480 shares · $212.5K · SEC
  • Oct 22, 2026 Kaye Mark Chief financial officer (CFO) Open-market sale 2,343 shares · $1.0M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +90

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)25.5
Rel. strength 60 d+9.0%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on ELV yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: ELV

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close